Published on 22 Feb 2024 on GuruFocus.com via Yahoo Finance
Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results
Collaboration Revenues: Increased to $47.9 million in Q4 and $78.6 million for the full year 2023.Research and Development Expenses: Rose to $53.0 million in Q4 and $189.1 million for the full year 2023.General and Administrative Expenses: Grew to $14.2 million in Q4 and $55.0 million for the full year 2023.Net Loss: Decreased to $14.4 million in Q4 and $147.0 million for the full year 2023.Cash Position: Strong with $745 million as of January 9, 2024, and runway into the first half of 2027.
Warning! GuruFocus has detected 5 Warning Sign with KYMR.
On February 22, 2024, Kymera Therapeutics Inc (NASDAQ:KYMR) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended December 31, 2023. The biotechnology company, known for its pioneering work in targeted protein degradation, reported significant advancements in its clinical programs and a robust financial position.